The FDA approved pembrolizumab in combination with paclitaxel, with or without bevacizumab, for adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS ≥1).
The FDA approved pembrolizumab (Keytruda) and Keytruda Qlex plus paclitaxel, with or without bevacizumab, for adults with PD-L1+ platinum-resistant ovarian carcinoma based on Phase 3 trial data showing improved survival outcomes.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07576621 |
Association Between Hypomagnesemia and Coagulopathy in Sepsis |
COMPLETED | |
| NCT07380542 |
Dynamic Magnesium Replacement Strategies and 28-Day Mortality in Non-Cardiac Critically Ill Patients With Hypomagnesemia: A Target Trial Emulation |
COMPLETED | |
| NCT07089004 |
Hypomagnesemia and Its Clinical Outcome |
COMPLETED | |
| NCT07056283 |
The Study of Urinary Biomarkers in Patients With Hypomagnesemia |
RECRUITING | |
| NCT06855550 |
Postoperative Incidence of Atrial Fibrillation Following Cardiac Surgery |
COMPLETED | |
| NCT06353750 |
Intracellular Magnesium and Heart Failure |
NOT_YET_RECRUITING | |
| NCT05998863 |
EffCaMgCit to Prevent Mineral Metabolism and Renal Complications of Chronic PPI Therapy |
RECRUITING | PHASE3 |
| NCT04426994 |
Hypomagnesemia Associated With Proton-Pump Inhibitor Use |
COMPLETED | |
| NCT04382157 |
Magnesium Replacement and Hyperglycemia After Kidney Transplantation |
UNKNOWN | PHASE1/PHASE2 |
| NCT04351451 |
Hypomagnesemia and Hypocalcemia Association Following Thyroidectomy |
COMPLETED |
